Kidney Cancer Research Bureau

non-for-profit research organization - Russian Federation & C.I.S.
Main     C.I.S. Situation     KCRB Staff     KCRB trials     Bank Account     League of patients      
KCRB studies
 

Kidney Cancer Research Bureau currently conducts 6 trials sponsored by the N.N. Blokhin Russian Cancer Research Center, other federal agencies, funds, and private industry. Each clinical study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Every clinical trial has a protocol, or action plan, for conducting the trial. The plan describes what will be done in the study, how it will be conducted, and why each part of the study is necessary. We are discussing our protocols and concept sheets with leading oncologists (specialists in kidney cancer) before start. In the Russian Federation, an independent ethical committee must approve and monitor the protocol. They make sure that that the risks are small and are worth the potential benefits.


Moreover, some of our studies are basic and translation.

 


 Trials

Size

Status

Efficacy of everolimus (AfinitorÒ) in metastatic renal cell carcinoma patients with failure on bevacizumab (sponsor: Novartis)

 37

patients

Active  
Preclinical efficacy of OM-RCA-01, humanized anti-FGFR1 monoclonal antibody in RCC models (sponsor: OncoMax)in vitro / in vivo Completed
KCRB-003 basic research "Evaluation plasma levels of bFGF and VEGF-A in MRCC patients treated with sunitinib"

38

patients

Completed

KCRB-002 basic research "Evaluation of expression and role of FGFR1 in renal cell carcinoma"

 140 

samples

Completed

Phase II study of Low molecular weight heparin in combination with Interferon-alpha for treatment of metastatic renal cell carcinoma

 200 patients

Completed

Radiofrequency ablation instead of palliative nephrectomy in metastatic renal cell carcinoma patients with small primary tumor

NCT00891475 >>

 114

patients

Completed

Independent review of sunitinib cancer-specific survival for metastatic renal cell carcinoma in Russia and C.I.S.

 102 patients

Completed

Testosterone for RCC patients with bone metastases.

Phase I/II study.

 21 patients 

Protocol, 

Not approved by sponsor

Phase II trial of Capecitabine for Non-clear cell RCC 

NCT01182142 >>

 

 51

patients

 

Completed

Sunitinib in patients with RCC and VHL disease 38 patients

 

Protocol, 

Not approved by sponsor

 

Temsirolimus with Low Molecular Weight Heparin in MRCC patients with porr prognosis 

Protocol,

Not approved by sponsor

IL-2 (Roncoleukine) in second-line of MRCC treatment (after TKI) in patients with favorable prognosis 92 patients Active 
Phase II trial of Capecitabine and Interferon-alpha after Interleukine-2 regimens in MRCC patients.48 patientsCompleted

 

  Last changes: 02 February 2012

  If you would like to become a SPONSOR, click >> We need support!